India, May 29 -- Shares of Alzamend Neuro, Inc. (ALZN) are gaining over 82% on Thursday morning after the company announced dosing of first patient in its phase II clinical trial of AL001.
ALZN is currently trading at $6.06, up $2.74 or 82.53%, on a huge volume of 41 million shares, above average volume of 131 thousand, on the Nasdaq. The stock opened its trading at $7.79 after closing Wednesday at $3.32. The stock has traded between $3.06 and $135.54 in the past 52-week period.
Alzamend Neuro, a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder, announced the dosing of the first patient of i...